226 related articles for article (PubMed ID: 33646555)
21. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
22. The bradykinin-forming cascade and its role in hereditary angioedema.
Kaplan AP; Joseph K
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
[TBL] [Abstract][Full Text] [Related]
23. Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability.
Diaz-Menindez M; Morgenstern-Kaplan D; Cuervo-Pardo L; Alvarez-Arango S; Gonzalez-Estrada A
Ther Clin Risk Manag; 2023; 19():313-317. PubMed ID: 37021074
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y; Marier JF; Kassir N; Chang C; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
[TBL] [Abstract][Full Text] [Related]
25. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
26. Current treatment of hereditary angioedema: An update on clinical studies.
Banerji A
Allergy Asthma Proc; 2010; 31(5):398-406. PubMed ID: 20929607
[TBL] [Abstract][Full Text] [Related]
27. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Davie RL; Edwards HJ; Evans DM; Hodgson ST; Stocks MJ; Smith AJ; Rushbrooke LJ; Pethen SJ; Roe MB; Clark DE; McEwan PA; Hampton SL
J Med Chem; 2022 Oct; 65(20):13629-13644. PubMed ID: 36251573
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ; Murugesan N; Li L; Rushbrooke LJ; Lee DK; De Donatis GM; Maetzel A; Yea CM; Hampton SL; Feener EP
Clin Exp Allergy; 2022 Sep; 52(9):1059-1070. PubMed ID: 35278245
[TBL] [Abstract][Full Text] [Related]
29. Lanadelumab: First Global Approval.
Syed YY
Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
[TBL] [Abstract][Full Text] [Related]
31. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.
Riedl MA; Soteres D; Sublett JW; Desai B; Tomita D; Collis P; Bernstein JA;
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):505-511.e1. PubMed ID: 38006972
[TBL] [Abstract][Full Text] [Related]
32. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
33. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
Jacobs J; Neeno T
Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
[TBL] [Abstract][Full Text] [Related]
34. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
35. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
36. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes.
Joseph K; Bains S; Tholanikunnel BG; Bygum A; Aabom A; Koch C; Farkas H; Varga L; Ghebrehiwet B; Kaplan AP
Allergy; 2015 Jan; 70(1):115-9. PubMed ID: 25186184
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
38. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
Joseph K; Tholanikunnel TE; Kaplan AP
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
[TBL] [Abstract][Full Text] [Related]
39. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
Watt M; Malmenäs M; Romanus D; Haeussler K
J Comp Eff Res; 2023 Jun; 12(6):e220188. PubMed ID: 37218553
[No Abstract] [Full Text] [Related]
40. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
